Windward Bio Nasdaq debut after $17 IPO lifts WWB 37%
Windward Bio Nasdaq debut after $17 IPO lifts WWB 37% in first session
- Windward Bio priced 10.3 million shares at $17 on Nov 12, raising $175 million plus $50 million from Sanofi.
- Shares opened at $18.35 on Nov 13, then rallied to $23.24 by 13:01 ET, up 27% from the open.
- Reuters reported the debut valued the Novo Holdings-backed biotech at about $1.07 billion.
- Lead asset WIN378 is a twice-yearly TSLP antibody for asthma and COPD, versus monthly Tezspire.
- Sanofi bought additional shares and warrants in a concurrent private placement.
- September interim Phase 2 asthma data and CEO Luca Santarelli’s prior exits supported demand.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.